Sonova Divests Sennheiser Consumer Audio Including Momentum 4 to Focus on Hearing Aids and Cochlear Implants

Sonova Holding AG announces divestment of its Sennheiser headphone business, home to the Momentum 4 headphones, to sharpen strategy on medical hearing solutions with a 6 billion CHF revenue target by 2031. US investors gain exposure to high-growth medtech amid short-term market caution.

Sonova Holding AG has announced plans to divest its consumer audio division, which includes the Sennheiser Momentum 4 headphones, to refocus exclusively on its core medical businesses of hearing aids and cochlear implants. This strategic shift aims to unlock long-term growth potential in the expanding medical hearing market, targeting 6 billion CHF in revenue by fiscal 2030/31, while near-term financial outlook remains cautious for 2025/26. For US investors, this positions Sonova as a pure-play medtech leader with strong innovation tailwinds, despite current share price pressures.

Updated: 26.03.2026

By Dr. Elena Voss, Senior Audio and Medtech Editor: Tracking the intersection of consumer electronics divestments and medical device growth in global hearing health markets.

Sonova's Strategic Divestment of Sennheiser Consumer Audio

Sonova's decision marks a pivotal realignment away from consumer electronics toward medical-grade hearing technologies. The consumer audio division, acquired through the partnership with Sennheiser's consumer headphone business, features flagship products like the Momentum 4 wireless headphones known for their active noise cancellation and 60-hour battery life.

This unit has been a notable but non-core part of Sonova's portfolio since the 2022 deal where Sonova took over distribution and development of Sennheiser's consumer audio line. The Momentum 4, launched in 2022, quickly gained acclaim for superior sound quality and comfort in the premium wireless headphone segment competing with Sony WH-1000XM5 and Bose QuietComfort Ultra.

Management conducted an internal strategic review leading to this divestment announcement. The move allows Sonova to allocate capital fully to hearing instruments and cochlear implants, segments with higher margins and regulatory moats.

The consumer audio business generated steady revenue but diluted focus amid rising demand for over-the-counter hearing aids and advanced implants. Divestment proceeds will bolster balance sheet strength for medical R&D investments.

Details on the sale process remain forthcoming, with Sonova committing to a structured exit that minimizes disruptions to ongoing operations. Employees and partners in the consumer division will receive support during the transition.

This shift aligns with broader industry trends where medtech firms streamline portfolios post-acquisition to maximize synergies in high-growth areas. For the Momentum 4 specifically, potential buyers could include audio specialists eyeing Sennheiser's brand equity.

Momentum 4 Headphones: Legacy in Premium Wireless Audio

The Sennheiser Momentum 4 stands as a benchmark in over-ear wireless headphones, blending audiophile-grade sound with practical features for daily use. Priced around $350, it offers aptX Adaptive codec support for high-res audio, customizable EQ via app, and adaptive ANC that rivals top competitors.

Battery life remains its killer feature at up to 60 hours with ANC on, far surpassing many rivals. Recent firmware updates have refined transparency mode and multipoint Bluetooth connectivity, addressing early user feedback.

In reviews, the Momentum 4 excels in neutral sound signature ideal for critical listening, with plush earcups ensuring comfort during extended sessions. It appeals to professionals, travelers, and audiophiles seeking value in the $300+ segment.

Sonova's stewardship enhanced integration with hearing health tech, including sound personalization features that preview medical applications. However, as a consumer product, it operated separately from Phonak's clinical hearing aids.

Market performance has been solid, with strong sales in North America where premium headphones see 10-15% annual growth. US consumers value the Momentum 4's build quality and Sennheiser heritage dating back decades.

Post-divestment, the product's future under new ownership could accelerate innovations like AI-driven sound optimization or integration with emerging spatial audio standards.

Competitive landscape includes Apple's AirPods Max and Sony's flagships, but Momentum 4's price-to-performance ratio sustains loyalty among Android and hi-fi users.

Shift to Medical Hearing Focus Drives Long-Term Targets

Sonova's core businesses in hearing aids and cochlear implants now receive undivided attention. Hearing instruments, under the Phonak brand, lead in prescription and OTC markets with OTC sales surging post-FDA approvals.

Cochlear implants represent high-value growth, targeting severe-to-profound hearing loss with advanced signal processing. Sonova's market share in this segment positions it ahead of peers like Cochlear Ltd.

The strategy update sets ambitious goals: 5-10% annual revenue growth and 7-12% core EBIT growth through 2030/31, culminating in 6 billion CHF revenue. This implies doubling current scale via organic expansion and market penetration.

Key enablers include AI-enhanced fitting algorithms, tele-audiology platforms, and miniaturization for discreet wearables. US market, with aging demographics, drives 40% of global hearing aid demand.

Regulatory tailwinds like expanded OTC access lower barriers, boosting volumes. Sonova's wholesale channel showed resilience, gaining share despite economic headwinds.

Innovation pipeline features next-gen rechargeable aids with 24+ hour life and Bluetooth LE Audio for seamless connectivity. Cochlear advancements target pediatric and adult expansions.

This medical pivot enhances Sonova's appeal as a stable medtech growth story, less exposed to consumer cyclicality.

Near-Term Financial Outlook Remains Subdued

For fiscal 2025/26, Sonova guides revenue growth to the lower end of 5-9% and normalized EBITA to the bottom of 14-18%. Challenges include inventory adjustments and softer demand in mature markets.

Despite this, operational momentum in wholesale supports margin stability. Cost discipline and pricing power in premium hearing segments provide buffers.

Currency headwinds from strong Swiss franc impact reported figures, but hedged exposures mitigate risks. Full-year results due May 18, 2026, will detail divestment progress.

Consumer audio divestment may incur one-off costs but promises cleaner earnings trajectory post-sale. Management emphasizes disciplined execution amid macro uncertainty.

US investors should note Sonova's ADR availability, offering direct exposure without FX complexity. Dividend policy remains progressive, supporting yield appeal.

Investor Context: Sonova Holding AG (CH0012549785)

Sonova Holding AG, listed on SIX Swiss Exchange under ISIN CH0012549785, trades as a mid-cap medtech stock. Recent strategy news drove a share surge, reflecting optimism on the medical refocus.

Year-to-date, shares faced pressure, down 16% amid broader sector rotation, hitting 52-week lows before rebounding. Valuation metrics suggest attractiveness relative to historical averages and peers.

US investors access via OTC markets or international brokers. Dividend yield around 1.5% complements growth prospects. Full-year report will clarify path to 2031 targets.

Strategic divestment reduces conglomerate discount, potentially catalyzing multiple expansion as a hearing pure-play.

Implications for US Audio and Hearing Markets

In the US, premium headphones like Momentum 4 hold steady share amid streaming boom. Divestment could spur aggressive marketing under new ownership, challenging Sony and Bose dominance.

Hearing health crisis affects 48 million adults, with OTC category exploding to $1B+ annually. Sonova's Phonak leads with user-friendly devices blending consumer appeal and clinical efficacy.

Investors eye demographic tailwinds: 10,000 Baby Boomers retire daily, amplifying demand. Policy expansions under Medicare could accelerate adoption.

Sonova's scale funds US R&D hubs, hastening innovations like AI diagnostics integrated with wearables. Partnership potential with Big Tech enhances ecosystem play.

Overall, the divestment clarifies Sonova's medtech trajectory, benefiting stakeholders seeking focused exposure.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.